NMOSD Patients At Greater Risk of Type 2 Diabetes A recent analysis found an elevated risk of type 2 diabetes among patients with neuromyelitis optica spectrum disorder, with steroid use possibly ...

Roche said that NMOSD will be launched in two weeks. This approval is supported by results from two randomised controlled phase 3 trials, the SAkuraStar and SAkuraSky studies.

A swift and accurate diagnosis is crucial when treating any disease, but especially a rare one. Sadly, people with particularly rare diseases that present like more recognisable conditions face a ...

The N-MOmentum pivotal trial (NCT02200770) is the largest phase 3 clinical trial in NMOSD and the only phase 3 trial that collected MRI data, which was incorporated into its attack adjudication ...

Immunoadsorption (IA) is regarded as an alternative therapy, but its efficacy and putative mechanism of action still needs to be established. Methods We prospectively treated 11 patients with ...